| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Angiotensin-converting enzyme (ACE)
|
|---|---|
| ln Vitro |
As a deuterium-labeled analogue, Enalaprilat-d5 is expected to retain the ACE inhibitory activity of its non-labeled parent compound. Enalaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits bradykinin degradation.
|
| ln Vivo |
Currently, no specific in vivo data is available for this deuterated compound. The non-deuterated parent enalaprilat is known to act as a vasodilator, decreasing total peripheral and renal vascular resistance, thereby lowering blood pressure in vivo.
|
| Enzyme Assay |
A typical ACE inhibition assay protocol involves incubating the test compound with ACE enzyme derived from rabbit lung or recombinant sources and a synthetic substrate like Hip-His-Leu. The reaction is performed in a borate buffer at 37degC. The product, hippuric acid, is extracted with ethyl acetate and quantified spectrophotometrically at 228 nm.
|
| Cell Assay |
Enalaprilat-d5 is used as an analytical standard and not typically employed in routine cell-based assays. General cellular uptake studies may involve HEK293 cells overexpressing organic anion transporters (OATs) to study renal active secretion. Cells are incubated with the compound, and intracellular concentrations are quantified by LC-MS/MS.
|
| Animal Protocol |
General in vivo protocols for ACE inhibitors include administering the compound to spontaneously hypertensive rats (SHRs) via oral gavage. Blood pressure is measured using tail-cuff plethysmography. For PK studies, blood samples are collected at various time points, and plasma concentrations are analyzed using LC-MS/MS with the deuterated compound as an internal standard.
|
| ADME/Pharmacokinetics |
Enalaprilat-d5 has a molecular weight of 353.43. As a deuterium-labeled compound, its pharmacokinetics are expected to be nearly identical to non-labeled enalaprilat. Enalaprilat is poorly absorbed orally and is typically administered intravenously. It is primarily excreted unchanged in the urine via glomerular filtration and active tubular secretion.
|
| Toxicity/Toxicokinetics |
Deuterium labeling does not alter toxicity profile. The parent compound, Enalaprilat, is generally well-tolerated but may cause hypotension, dizziness, and hyperkalemia in overdose. As with other ACE inhibitors, it is contraindicated in pregnancy due to the risk of fetal toxicity. No specific toxicology data is available for the d5 analog.
|
| Additional Infomation |
Enalaprilat-d5 is not a drug but a research tool. It is primarily used as an internal standard for the quantification of enalaprilat in biological samples using techniques like LC-MS/MS. This application is crucial for pharmacokinetic studies, bioequivalence testing, and therapeutic drug monitoring. No clinical trials or approved uses exist for this specific isotope-labeled product.
|
| Molecular Formula |
C18H19D5N2O5
|
|---|---|
| Molecular Weight |
353.42
|
| Exact Mass |
353.199
|
| CAS # |
349554-00-3
|
| Related CAS # |
Enalaprilat dihydrate;84680-54-6;Enalaprilat-d5 sodium;1356922-29-6;Enalaprilat;76420-72-9
|
| PubChem CID |
3691183
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
601.0±55.0 °C at 760 mmHg
|
| Flash Point |
317.3±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.580
|
| LogP |
1.54
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
25
|
| Complexity |
490
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C(=O)N1CCCC1C(=O)O)NC(CCC2=CC=CC=C2)C(=O)O
|
| InChi Key |
LZFZMUMEGBBDTC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)
|
| Chemical Name |
1-[2-[(1-carboxy-3-phenylpropyl)amino]propanoyl]pyrrolidine-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (282.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.07 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8295 mL | 14.1475 mL | 28.2949 mL | |
| 5 mM | 0.5659 mL | 2.8295 mL | 5.6590 mL | |
| 10 mM | 0.2829 mL | 1.4147 mL | 2.8295 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
